Hemab Therapeutics Shares Positive Data on Bleeding Disorder Pipeline
Sutacimig Phase 2 interim results demonstrate >50% reduction in treated bleeding event and prophylactic treatment potential in Glanzmann thrombasthenia HMB-002 clinical proof-of-mechanism data in Von Willebrand...